• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    12 Health Care Stocks Moving In Friday's Pre-Market Session

    3/24/23 9:06:13 AM ET
    $CATX
    $DRMA
    $HCTI
    $IMPL
    Medical/Dental Instruments
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $CATX alert in real time by email

    Gainers

    • Assure Hldgs (NASDAQ:IONM) shares moved upwards by 17.1% to $4.39 during Friday's pre-market session. The company's market cap stands at $4.8 million.
    • Dermata Therapeutics (NASDAQ:DRMA) shares increased by 16.68% to $1.96. The company's market cap stands at $1.6 million.
    • Impel Pharmaceuticals (NASDAQ:IMPL) shares rose 12.97% to $1.48. The market value of their outstanding shares is at $35.1 million. The company's, Q4 earnings came out today.
    • Molecular Templates (NASDAQ:MTEM) shares moved upwards by 11.31% to $0.37. The market value of their outstanding shares is at $20.8 million.
    • Vivani Medical (NASDAQ:VANI) stock rose 10.89% to $1.12. The company's market cap stands at $56.8 million.
    • cbdMD (AMEX:YCBD) stock moved upwards by 10.58% to $0.21. The company's market cap stands at $13.7 million.

    Losers

    • Healthcare Triangle (NASDAQ:HCTI) stock decreased by 11.2% to $0.38 during Friday's pre-market session. The company's market cap stands at $15.8 million.
    • Minerva Surgical (NASDAQ:UTRS) shares decreased by 11.13% to $0.2. The market value of their outstanding shares is at $35.4 million. The company's, Q4 earnings came out 3 days ago.
    • Pluri (NASDAQ:PLUR) shares declined by 10.87% to $0.82. The company's market cap stands at $33.4 million.
    • Perspective Therapeutics (AMEX:CATX) stock fell 10.45% to $0.6. The market value of their outstanding shares is at $167.1 million.
    • Midatech Pharma (NASDAQ:MTP) shares decreased by 8.55% to $0.32. The company's market cap stands at $2.2 million.
    • Lucid Diagnostics (NASDAQ:LUCD) shares declined by 7.92% to $1.28. The company's market cap stands at $55.5 million. See Also: www.benzinga.com/money/best-healthcare-stocks/

    This article was generated by Benzinga's automated content engine and reviewed by an editor.

    Get the next $CATX alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $CATX
    $DRMA
    $HCTI
    $IMPL

    CompanyDatePrice TargetRatingAnalyst
    Perspective Therapeutics Inc.
    $CATX
    2/19/2026$16.00Overweight
    Piper Sandler
    Perspective Therapeutics Inc.
    $CATX
    11/24/2025$12.00Buy
    Truist
    Perspective Therapeutics Inc.
    $CATX
    10/10/2025$14.00Buy
    BTIG Research
    Perspective Therapeutics Inc.
    $CATX
    3/13/2025$10.00Buy
    H.C. Wainwright
    Perspective Therapeutics Inc.
    $CATX
    3/7/2025$15.00Sector Outperform
    Scotiabank
    Perspective Therapeutics Inc.
    $CATX
    11/25/2024$24.00 → $5.00Buy → Neutral
    BofA Securities
    Perspective Therapeutics Inc.
    $CATX
    10/24/2024$20.00Buy
    UBS
    Perspective Therapeutics Inc.
    $CATX
    10/1/2024$25.00Outperform
    Wedbush
    More analyst ratings

    $CATX
    $DRMA
    $HCTI
    $IMPL
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Williams Gregg bought $1,983,333 worth of shares (1,866,492 units at $1.06) (SEC Form 4)

    4 - Vivani Medical, Inc. (0001266806) (Issuer)

    2/17/26 6:01:47 AM ET
    $VANI
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Director Williams Gregg bought $1,999,999 worth of shares (1,351,351 units at $1.48) (SEC Form 4)

    4 - Vivani Medical, Inc. (0001266806) (Issuer)

    1/28/26 10:01:22 AM ET
    $VANI
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Director Williams Gregg bought $1,983,334 worth of shares (1,737,765 units at $1.14) (SEC Form 4)

    4 - Vivani Medical, Inc. (0001266806) (Issuer)

    1/20/26 9:00:37 AM ET
    $VANI
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $CATX
    $DRMA
    $HCTI
    $IMPL
    SEC Filings

    View All

    Amendment: SEC Form SCHEDULE 13D/A filed by Dermata Therapeutics Inc.

    SCHEDULE 13D/A - Dermata Therapeutics, Inc. (0001853816) (Subject)

    2/23/26 7:56:24 PM ET
    $DRMA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SCHEDULE 13G/A filed by Dermata Therapeutics Inc.

    SCHEDULE 13G/A - Dermata Therapeutics, Inc. (0001853816) (Subject)

    2/18/26 4:49:52 PM ET
    $DRMA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SCHEDULE 13G/A filed by Dermata Therapeutics Inc.

    SCHEDULE 13G/A - Dermata Therapeutics, Inc. (0001853816) (Subject)

    2/17/26 9:48:09 PM ET
    $DRMA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CATX
    $DRMA
    $HCTI
    $IMPL
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Piper Sandler initiated coverage on Perspective Therapeutics with a new price target

    Piper Sandler initiated coverage of Perspective Therapeutics with a rating of Overweight and set a new price target of $16.00

    2/19/26 7:52:02 AM ET
    $CATX
    Medical/Dental Instruments
    Health Care

    Truist resumed coverage on Perspective Therapeutics with a new price target

    Truist resumed coverage of Perspective Therapeutics with a rating of Buy and set a new price target of $12.00

    11/24/25 9:17:24 AM ET
    $CATX
    Medical/Dental Instruments
    Health Care

    BTIG Research initiated coverage on Perspective Therapeutics with a new price target

    BTIG Research initiated coverage of Perspective Therapeutics with a rating of Buy and set a new price target of $14.00

    10/10/25 8:39:44 AM ET
    $CATX
    Medical/Dental Instruments
    Health Care

    $CATX
    $DRMA
    $HCTI
    $IMPL
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    FDA Approval for TRUDHESA issued to IMPEL NEUROPHARMA INC

    Submission status for IMPEL NEUROPHARMA INC's drug TRUDHESA (ORIG-1) with active ingredient DIHYDROERGOTAMINE MESYLATE has changed to 'Approval' on 09/02/2021. Application Category: NDA, Application Number: 213436, Application Classification: Type 5 - New Formulation or New Manufacturer

    9/13/21 2:21:35 PM ET
    $IMPL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    FDA Approval for DIHYDROERGOTAMINE MESYLATE issued to IMPEL NEUROPHARMA INC

    Submission status for IMPEL NEUROPHARMA INC's drug DIHYDROERGOTAMINE MESYLATE (ORIG-1) with active ingredient DIHYDROERGOTAMINE MESYLATE has changed to 'Approval' on 09/02/2021. Application Category: NDA, Application Number: 213436, Application Classification: Type 5 - New Formulation or New Manufacturer

    9/7/21 1:04:43 PM ET
    $IMPL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CATX
    $DRMA
    $HCTI
    $IMPL
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Pluri Secures Global IP Position with China Patent Grant for Large-Scale Immune Cell Expansion, Complementing Prior U.S. Patent

    Expands patent protection across major global pharmaceutical markets, including the U.S., China and Asia-Pacific Enables scalable, automated manufacturing of diverse immune cell therapies using proprietary 3D expansion technology Strengthens positioning in China's growing cell therapy market and supports cross-border partnerships  HAIFA, Israel, Feb. 18, 2026 (GLOBE NEWSWIRE) -- Pluri Inc. ("Pluri", the "Company", "we", "our" or "us") (Nasdaq and TASE: PLUR ), a leading biotechnology company leveraging its proprietary platform for cell-based solutions to create a collaborative network of ventures, today announces that the China National Intellectual Property Administration (CNIPA) has gra

    2/18/26 8:00:00 AM ET
    $PLUR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    cbdMD Reports Sequential Revenue Growth, Improved Liquidity, and Strong Start to Fiscal 2026

    CHARLOTTE, N.C., Feb. 17, 2026 /PRNewswire/ -- cbdMD, Inc. (NYSE:YCBD), one of the nation's leading and most highly trusted and recognized CBD companies, and operator of the leading CBD brands cbdMD, Bluebird Botanicals, Paw CBD, along with its THC beverage brand Oasis today announced its financial results for the first quarter of fiscal year ended December 31, 2025. cbdMD reported 12% sequential revenue growth and improved liquidity in the first quarter of fiscal 2026, reflecting continued stabilization of the core business and early benefits from recent strategic actions."We a

    2/17/26 4:10:00 PM ET
    $YCBD
    Package Goods/Cosmetics
    Consumer Discretionary

    New Treatment Modalities Are Reaching Cancers That Resisted Everything Else

    Issued on behalf of Oncolytics Biotech Inc.VANCOUVER, BC, Feb. 17, 2026 /CNW/ -- Equity-Insider.com News Commentary – More than 2,100 oncology clinical trials were initiated globally in 2024, with targeted therapies representing the fastest-growing subsegment and over 100 antibody-drug conjugates now in active clinical development[1]. That pipeline depth extends to radiopharmaceuticals, cell therapies, and device-based platforms now generating survival data in tumor types that have resisted conventional approaches for decades. Oncolytics Biotech Inc. (NASDAQ:ONCY), Novocure (NASDAQ:NVCR), Perspective Therapeutics, Inc. (NYSE-A: CATX), ImmunityBio, Inc. (NASDAQ:IBRX), and Nuvation Bio Inc. (N

    2/17/26 11:17:00 AM ET
    $CATX
    $IBRX
    $NUVB
    Medical/Dental Instruments
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)
    Biotechnology: Pharmaceutical Preparations

    $CATX
    $DRMA
    $HCTI
    $IMPL
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Williams Gregg bought $1,983,333 worth of shares (1,866,492 units at $1.06) (SEC Form 4)

    4 - Vivani Medical, Inc. (0001266806) (Issuer)

    2/17/26 6:01:47 AM ET
    $VANI
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Director Williams Gregg bought $1,999,999 worth of shares (1,351,351 units at $1.48) (SEC Form 4)

    4 - Vivani Medical, Inc. (0001266806) (Issuer)

    1/28/26 10:01:22 AM ET
    $VANI
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Director Williams Gregg bought $1,983,334 worth of shares (1,737,765 units at $1.14) (SEC Form 4)

    4 - Vivani Medical, Inc. (0001266806) (Issuer)

    1/20/26 9:00:37 AM ET
    $VANI
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $CATX
    $DRMA
    $HCTI
    $IMPL
    Leadership Updates

    Live Leadership Updates

    View All

    Lucid Diagnostics Appoints Healthcare Industry Veteran John R. Palumbo to Board of Directors

    Growth-focused healthcare executive brings 40 years of executive leadership experience across multiple industry sectors NEW YORK, Sept. 25, 2025 /PRNewswire/ -- Lucid Diagnostics Inc. (NASDAQ: LUCD) ("Lucid" or the "Company"), a commercial-stage, cancer prevention medical diagnostics company and subsidiary of PAVmed Inc. (NASDAQ: PAVM), today announced the appointment of accomplished healthcare executive John R. Palumbo to its Board of Directors, effective September 22, 2025. "John is a highly accomplished executive whose 40 years of healthcare leadership experience spans earl

    9/25/25 8:01:00 AM ET
    $LUCD
    $MDRX
    $PAVM
    Medical/Dental Instruments
    Health Care
    EDP Services
    Technology

    Lucid Diagnostics Appoints Danielle Scelfo as Senior Vice President, Market Access & Government Affairs

    Scelfo to strengthen and scale Lucid's market access infrastructure ahead of key upcoming reimbursement milestones—including Medicare coverage for EsoGuard—and to accelerate commercial coverage expansion NEW YORK, Sept. 16, 2025 /PRNewswire/ -- Lucid Diagnostics Inc. (NASDAQ:LUCD) ("Lucid" or the "Company"), a commercial-stage cancer prevention medical diagnostics company and subsidiary of PAVmed Inc. (NASDAQ:PAVM), today announced the appointment of Danielle Scelfo as Senior Vice President, Market Access & Government Affairs, reporting to the Chief Executive Officer. Ms. Scelfo is widely recognized in the diagnostics industry as an accomplished health policy leader with more than 25 years o

    9/16/25 8:01:00 AM ET
    $LUCD
    $PAVM
    Medical/Dental Instruments
    Health Care

    Perspective Therapeutics Appoints Biotech Veteran Joel Sendek as Chief Financial Officer

    SEATTLE, Sept. 04, 2025 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. ("Perspective" or the "Company") (NYSE:CATX), a radiopharmaceutical company pioneering advanced treatments for cancers throughout the body, today announced the appointment of Joel Sendek as the Company's Chief Financial Officer, effective today. Mr. Sendek brings extensive experience in senior corporate roles in biotech finance and as a highly respected senior equity research analyst at a number of leading firms. Mr. Sendek previously served as CFO at four biotech companies: Dewpoint Therapeutics, Sema4, Spero Therapeutics, and Forward Pharma. He has a successful track record in corporate finance, having completed

    9/4/25 7:00:00 AM ET
    $CATX
    Medical/Dental Instruments
    Health Care

    $CATX
    $DRMA
    $HCTI
    $IMPL
    Financials

    Live finance-specific insights

    View All

    cbdMD Reports Sequential Revenue Growth, Improved Liquidity, and Strong Start to Fiscal 2026

    CHARLOTTE, N.C., Feb. 17, 2026 /PRNewswire/ -- cbdMD, Inc. (NYSE:YCBD), one of the nation's leading and most highly trusted and recognized CBD companies, and operator of the leading CBD brands cbdMD, Bluebird Botanicals, Paw CBD, along with its THC beverage brand Oasis today announced its financial results for the first quarter of fiscal year ended December 31, 2025. cbdMD reported 12% sequential revenue growth and improved liquidity in the first quarter of fiscal 2026, reflecting continued stabilization of the core business and early benefits from recent strategic actions."We a

    2/17/26 4:10:00 PM ET
    $YCBD
    Package Goods/Cosmetics
    Consumer Discretionary

    cbdMD, Inc. to Host Conference Call to Discuss December 31, 2025 First Quarter Results

    CHARLOTTE, N.C., Feb. 12, 2026 /PRNewswire/ -- cbdMD, Inc. (NYSE:YCBD), one of the nation's leading, highly trusted and widely recognized CBD companies, today announces that it will host a conference call at 4:20 p.m., Eastern Time, on Tuesday, February 17, 2026, to discuss the company's December 31, 2025 first quarter financial results and business progress. CONFERENCE CALL DETAILS Tuesday, February 17, 2026, 4:20 p.m. Eastern Time USA/Canada: 888-880-3330 Webcast/Webcast Replay link - available through February 17, 2027: https://app.webinar.net/YzX7D4ynvN2 About cbdMD, Inc.

    2/12/26 5:31:00 PM ET
    $YCBD
    Package Goods/Cosmetics
    Consumer Discretionary

    cbdMD Reports Third Consecutive Year of Operating Improvement, Strengthens Balance Sheet, and Regains NYSE American Continued Listing Compliance

    CHARLOTTE, N.C., Dec. 19, 2025 /PRNewswire/ -- cbdMD, Inc. (NYSE:YCBD), one of the nation's leading and most highly trusted and recognized CBD companies, and operator of the leading CBD brands cbdMD and Paw CBD, along with hemp derived THC beverage line Herbal Oasis today announced our financial results for the full fiscal year ended September 30, 2025. For fiscal year 2025, cbdMD delivered its third consecutive year of operational and financial improvement, reflecting disciplined cost management, focused execution, and continued investment in quality and science. The Company

    12/19/25 4:10:00 PM ET
    $YCBD
    Package Goods/Cosmetics
    Consumer Discretionary

    $CATX
    $DRMA
    $HCTI
    $IMPL
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by Lucid Diagnostics Inc.

    SC 13D/A - Lucid Diagnostics Inc. (0001799011) (Subject)

    12/12/24 4:30:32 PM ET
    $LUCD
    Medical/Dental Instruments
    Health Care

    Amendment: SEC Form SC 13G/A filed by Molecular Templates Inc.

    SC 13G/A - Molecular Templates, Inc. (0001183765) (Subject)

    11/18/24 9:49:56 PM ET
    $MTEM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by Perspective Therapeutics Inc.

    SC 13G - Perspective Therapeutics, Inc. (0000728387) (Subject)

    11/14/24 6:14:40 PM ET
    $CATX
    Medical/Dental Instruments
    Health Care